Quidditas Funding News- Belgian BioTech Startup Quidditas Raises €2.62Mn Funding

This includes a €900,000 investment led by French biotech fund iXLife Capital, with participation from Key Ventures, family-owned companies, and business angels. Additionally, the company received a €1.72 million grant from the Walloon government's Win4Company program, which supports innovative enterprises in Belgium's Walloon region.

“Genome editing holds immense promise, especially in treating rare and complex genetic disorders. At Quidditas, our goal is to push the boundaries of what’s possible by developing a precise and adaptable solution that can address critical medical needs,” said François Cherbonneau, CEO and Co-founder of Quidditas. “We are grateful for the investors backing us, bringing us one step closer to making our vision of transforming healthcare through genomic medicine come true. We would also like to thank the Walloon region for its support, as this grant will help reinforce Belgium’s role as a key player in European biotech innovation and bioproduction.”

Quidditas Therapeutics is a biotech company founded in 2021, specializing in a new genome editing platform called GREAT (Gene REcombination Along with Transposase technology). This platform enables precise and adaptable genetic recombination, with applications in gene therapy, protein production, and regenerative medicine.

Read Also - Be.EV signs £20M deal with Schroders Capital to roll out Ultra-Rapid EV chargers

Quidditas is a biotechnology company founded by Dr. François Cherbonneau and Dr. Aurore Prunevieille, both of whom hold PhDs and Master's degrees in Engineering. They have experience working at renowned institutions like Paris Saint-Louis Hospital in France and Massachusetts General Hospital/Harvard Medical School in the United States. Their doctoral research focused on molecular genetics and immunology.

Quidditas aims to revolutionize gene therapy by enabling large, precise genetic modifications. This approach has the potential to treat complex and rare diseases that were previously considered untreatable. Additionally, their technology could open new possibilities in areas such as bioproduction, stem cell research, and other biomedical fields.

“iXLife is committed to backing companies that are capable of revolutionising the BioTech space,” said Jean-Pierre Kinet, MD, managing partner at iXLife Capital, immunologist and Emeritus Professor at Harvard Medical School. “Quidditas’ genome editing technology represents a transformative leap forward in the field, with the potential to address some of the most challenging diseases. We are excited to support its mission to bring impactful solutions to patients in need.”

Quidditas Therapeutics has developed a gene-editing technology designed to overcome the limitations of existing methods like CRISPR, which can face challenges with efficiency, precision, and the ability to insert large DNA segments.

Their technology enables scientists to precisely cut and insert both single- and double-stranded DNA or RNA at specific locations within the genome. This allows for the replacement of entire genes or exons by removing targeted sequences and inserting new, fully double-stranded ones. Such precise control facilitates complete gene recombination, addressing current technical challenges in gene therapy.Their technology also holds promise for applications in bioproduction, stem cell research, and other areas of biotechnology.

About QuidditasTherapeutics

Quidditas Therapeutics is a biotechnology company based in Belgium. It is developing a new genome editing technology called GREAT.The company aims to use this technology in gene therapy, protein production, and regenerative medicine.